Initial preclinical investigation of aclarubicin treatment in primary cutaneous T-cell lymphoma cells
Fenna J de Bie, Morgann D Dettingmeijer, Sanne de Haan, Willem H Zoutman, Sabina Y van der Zanden, Cornelis P Tensen, Ferenc A Scheeren, Jacques Neefjes, Maarten H Vermeer · 2026
Read Initial preclinical investigation of aclarubicin treatment in primary cutaneous T-cell lymphoma cells by Fenna J de Bie, Morgann D Dettingmeijer, Sanne de Haan, Willem H Zoutman, Sabina Y van der Zanden, Cornelis P Tensen, Ferenc A Scheeren, Jacques Neefjes, Maarten H Vermeer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579395.txt.
Description
Fenna J de Bie and colleagues tested aclarubicin, a cancer drug, on cells taken from patients with skin T-cell lymphoma, a rare skin lymphoma. Old drugs in this class, such as doxorubicin, harm the heart and so have strict dose limits, while aclarubicin harms chromatin with no such build-up of heart harm. Tumour cells and normal CD4 T cells were both exposed to a set of these drugs in lab dishes.
With a brief two-hour dose that mimics blood levels in patients, aclarubicin killed tumour cells at far lower doses than the rest, with a half-kill dose eight to twenty times lower. It also did better when T cells were switched on. The drug merits more lab and clinic tests in this lymphoma.
Catalog record
| CREATOR | Fenna J de Bie, Morgann D Dettingmeijer, Sanne de Haan, Willem H Zoutman, Sabina Y van der Zanden, Cornelis P Tensen, Ferenc A Scheeren, Jacques Neefjes, Maarten H Vermeer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |